SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Pharma Scien - Quaterly Results

30 Jan 2025 Evaluate
The sales figure stood at Rs. 5509.17 millions for the December 2024 quarter. The mentioned figure indicates a growth of about 45.12% as compared to Rs. 3796.36 millions during the year-ago period.The Total Profit for the quarter ended December 2024 of Rs. 149.38 millions grew from Rs.-602.85 millionsOperating Profit saw a handsome growth to 765.25 millions from 63.68 millions in the quarter ended December 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 5509.17 3796.36 45.12 17156.25 14075.59 21.89 21532.58 18544.96 16.11
Other Income 24.28 49.00 -50.45 378.05 360.11 4.98 723.06 840.66 -13.99
PBIDT 765.25 63.68 1101.71 2359.61 1314.85 79.46 3275.82 1825.43 79.45
Interest 342.14 362.40 -5.59 1312.45 1145.83 14.54 1679.28 1386.82 21.09
PBDT 422.94 -351.63 -220.28 1046.89 116.11 801.64 1542.89 288.61 434.59
Depreciation 209.18 215.23 -2.81 632.17 660.12 -4.23 846.68 936.21 -9.56
PBT 213.76 -566.86 -137.71 414.72 -544.01 -176.23 696.21 -647.60 -207.51
TAX 64.38 35.99 78.88 73.07 46.30 57.82 41.30 -694.42 -105.95
Deferred Tax 7.03 32.50 -78.37 35.35 18.16 94.66 38.18 -195.99 -119.48
PAT 149.38 -602.85 -124.78 341.65 -590.31 -157.88 654.91 46.82 1298.78
Equity 921.63 918.86 0.30 921.63 919.10 0.28 919.00 903.03 1.77
PBIDTM(%) 13.89 1.68 728.10 13.75 9.34 47.23 15.21 9.84 54.55

Strides Pharma Scien Share Price

1000.70 6.80 (0.68%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×